Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MLH1 deletion

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

MSI-H/dMMR + MLH1 deletion + PMS2 deletion (3)

MSI-H/dMMR + MLH1 deletion (2)

ER positive + MLH1 1835del3 + MSI-H/dMMR + TMB-H (1)

MLH1 methylation + MSI-H/dMMR (1)

MLH1 methylation + MSI-H/dMMR + TMB-H (1)

MSH6 mutation + MLH1 mutation + MSI-H (1)

MSI-H/dMMR + MLH1 negative + PMS2 negative (1)

MSI-H/dMMR + MLH1 deletion + PMS2 deletion (3)

MSI-H/dMMR + MLH1 deletion (2)

ER positive + MLH1 1835del3 + MSI-H/dMMR + TMB-H (1)

MLH1 methylation + MSI-H/dMMR (1)

MLH1 methylation + MSI-H/dMMR + TMB-H (1)

MSH6 mutation + MLH1 mutation + MSI-H (1)

MSI-H/dMMR + MLH1 negative + PMS2 negative (1)

›

MLH1 deletion	Endometrial Adenocarcinoma	MLH1 deletion	Endometrial Adenocarcinoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
MLH1 deletion	Prostate Cancer	MLH1 deletion	Prostate Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
MLH1 deletion	Colon Cancer	MLH1 deletion	Colon Cancer	cetuximab Resistant: D – Preclinical cetuximab Resistant : D	cetuximab Resistant: D – Preclinical cetuximab Resistant : D